
Opinion|Videos|July 29, 2024
Limitations of NCCN PD-L1 Expression Recommendations
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How could emergingoverall survival data from trials like
POSEIDON andKEYNOTE-189 impact future treatment guidelines and our understanding of long-term outcomes?
- What evidence supports using dual checkpoint inhibitor therapy plus chemotherapy over chemotherapy alone in the first-line driver-negative setting?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Hereditary Ovarian Cancer Genes Found Beyond Traditionally High-Risk Groups
2
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
3
ACIP Delayed Hepatitis B Vaccine Schedule Vote Amid Safety Controversy
4
Medicaid Expansion Associated With Lower Mortality in NSCLC
5












































